Respiratory Diseases |
Lung Diseases; Pleurisy |
Clinical Trial: Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration
This study has been completed.
Purpose
To determine the effect of corticosteroids, administered 24 to 48 hours before parturition, on the incidence of neonatal respiratory distress syndrome (RDS) and to determine whether the therapy has any adverse short- or long-term (up to 36 months) effects on the infant. Secondarily, to determine whether the therapy has any adverse short-term effects on the mother and to determine whether morbidity rates for neonatal respiratory distress syndrome as well as total and cause-specific infant mortality rates differ between mothers who received antenatal steroids and those who received conventional medical care.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Lung Diseases Respiratory Distress Syndrome | Drug: dexamethasone | Phase III |
MedlinePlus related topics: Premature Babies; Respiratory Diseases
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control
Study start: June 1976
BACKGROUND: Neonatal respiratory distress syndrome is one of the leading causes of disability and death in the newborn. In the United States, approximately 10 percent of all infants are premature, and each year about 50,000 cases of neonatal respiratory distress syndrome occur.
Extensive studies in animal models on respiratory distress syndrome have demonstrated that antenatal administration of synthetic (dexamethasone) and natural (cortisol) corticosteroids accelerates lung maturation and significantly diminishes the occurrence of RDS. Although a variety of conditions in newborn infants have been treated with steroids over the past 20 years without adverse effects, investigations have been needed on the short-term effects of corticosteroids administered antenatally on neonate and mother and on the long-term effects on the infant.
The Planning Phase of this trial was completed in March 1977, with formulation of a common protocol and manual of operations. Patient screening and enrollment began in August 1977 and ended on March 1, 1980. Follow-up ended in August 1983 and data analysis was completed October 31, 1983.
DESIGN NARRATIVE: Randomized, double-blind, fixed sample. Six hundred and ninety-six pregnant women were randomized to four doses of dexamethasone every 12 hours or to placebo. Endpoints were the incidence of respiratory distress syndrome and abnormality of motor-neuro-intellectual development in their infants.
Eligibility
Ages Eligible for Study: up to 1 Year, Genders Eligible for Study: Both
Criteria
Location Information
Charles Bauer, University of Miami
Richard Depp, Northwestern University
Sheldon Korones, University of Tennessee
Henrique Rigatto, University of Manitoba
Richard Zachman, University of Wisconsin
More Information
Publications
[No authors listed] Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol. 1981 Oct 1;141(3):276-87.
[No authors listed] Effects of antenatal dexamethasone administration in the infant: long-term follow-up. J Pediatr. 1984 Feb;104(2):259-67.
Collaborative Group on Antenatal Steroid Therapy: Prevention of Respiratory Distress Syndrome: Effect of Antenatal Dexamethasone Administration. Hospital and Follow-up Studies. NIH Publication No. 85-2695, 1985.
Record last reviewed: January 2000
Last Updated: October 13, 2004
Record first received: October 27, 1999
ClinicalTrials.gov Identifier: NCT00000563
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Adult (Acute) Respiratory Distress Syndrome (ARDS) (American Lung Association)
- African Americans and Lung Disease (American Lung Association)

Not Signed In -

